Cytokinetics Posts First Full MYQORZO Quarter as Armistice Capital Adds to Its Position

Cytokinetics booked its first full quarter of MYQORZO sales on Aug. 6. Armistice Capital used the same three months to raise its stake in the company, at a time when several biopharma-focused hedge funds were absorbing losses on concentrated bets elsewhere in the industry. MYQORZO’s First Full Quarter Cytokinetics reported $25.3 million in net product Read More: https://punchng.com/cytokinetics-posts-first-full-myqorzo-quarter-as-armistice-capital-adds-to-its-position/